西陇科学股份有限公司章程 二〇二五年四月 | 第一章 | 总则 | 4 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 6 | | 第三章 | 股份 | 7 | | | 第一节 股份发行 | 7 | | | 第二节 股份增减和回购 | 7 | | | 第三节 股份转让 | 8 | | 第四章 | 股东和股东大会 | 10 | | | 第一节 股东 | 10 | | | 第二节 股东大会的一般规定 | 12 | | | 第三节 股东大会的召集 | 16 | | | 第四节 股东大会的提案与通知 | 17 | | | 第五节 股东大会的召开 | 19 | | | 第六节 股东大会的表决和决议 | 21 | | 第五章 | 董事会 | 26 | | | 第一节 董事 | 26 | | | 第二节 董事会 | 28 | | | 第三节 独立董事 | 34 | | 第六章 | 总裁及其他高级管理人员 | 39 | | 第七章 | 监事会 | 41 | | | 第一节 监事 | 41 | | | 第二节 监事会 | 41 | | 第八章 | | 财务会计制度、利润分配和审计 44 | | ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥1,723,911,446.26, a decrease of 10.93% compared to ¥1,935,429,780.12 in the same period last year[5] - Net profit attributable to shareholders increased by 22.59% to ¥8,638,951.94 from ¥7,046,896.18 year-on-year[5] - The company reported a total of RMB 3,422,374,492.16 in current assets, an increase from RMB 3,287,777,849.87[13] - Total operating revenue decreased to ¥1,723,911,446.26 from ¥1,935,429,780.12, a decline of approximately 10.9% year-over-year[16] - Net profit increased to ¥8,957,870.83 from ¥7,263,074.61, representing a growth of approximately 23.3% year-over-year[17] - The total comprehensive income for the period was ¥8,964,243.79 compared to a loss of ¥67,223,564.84 in the previous period, showing a substantial turnaround[18] Cash Flow - The net cash flow from operating activities surged by 1,474.84% to ¥79,415,487.75, compared to ¥5,042,775.40 in the previous year[5] - Cash inflow from operating activities decreased to ¥1,863,781,431.44 from ¥2,466,064,277.67, a decline of about 24.4% year-over-year[19] - Total cash outflow from operating activities amounted to $1,784,365,943.69, down from $2,461,021,502.27, reflecting improved cash management[20] - The net cash flow from investing activities was -$18,400,711.13, an improvement from -$67,167,888.32, suggesting better investment efficiency[20] - Cash inflow from financing activities was $101,345,585.69, compared to $359,902,261.85 in the previous period, indicating a decrease in financing activities[20] - The net cash flow from financing activities was -$109,739,434.55, a decline from $36,759,763.89, highlighting challenges in financing[20] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,841,141,343.99, reflecting a 2.66% increase from ¥4,715,579,071.58 at the end of the previous year[5] - The total liabilities increased to ¥2,525,063,576.39 from ¥2,409,792,792.73, an increase of about 4.8% year-over-year[14] - The company's total liabilities included accounts payable of RMB 676,587,567.61, up from RMB 615,763,209.95[13] - Contract liabilities rose by 42.05% to ¥62,544,039.68, attributed to an increase in advance payments received compared to the same period last year[7] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 80,499, with the largest shareholder holding 9.65% of the shares[8] - The company's basic earnings per share remained stable at ¥0.01, unchanged from the previous year[5] - Basic and diluted earnings per share remained stable at ¥0.01 for both periods[18] Other Financial Metrics - Deferred tax assets increased by 28.17% to ¥17,774,047.47, primarily due to an increase in recognized deferred tax assets[7] - Other income decreased by 38.93% to ¥8,044,225.65, mainly due to a reduction in government subsidies received during the reporting period[7] - The company reported a significant increase in credit impairment losses, which rose by 77.16% to ¥19,684,170.15, due to an increase in bad debt provisions[7] - Research and development expenses decreased to ¥19,695,576.61 from ¥27,256,625.41, a reduction of approximately 27.8% year-over-year[17] - Other comprehensive income after tax increased to ¥6,372.96 from a loss of ¥74,486,639.45, indicating a significant recovery[18] Compensation Commitments - The company committed to a net profit of no less than RMB 49 million for 2022, RMB 63 million for 2023, and RMB 78 million for 2024 from the acquisition of Aikewei Biotechnology[10] - The company has not yet determined whether it will bear compensation obligations related to the performance commitments of Aikewei Biotechnology[11]

Financial Performance - The company reported a significant increase in revenue, with a year-on-year growth of 15% in the last fiscal year[13]. - The company's operating revenue for 2024 reached ¥7,816,465,794, representing a 10.22% increase compared to ¥7,091,743,412 in 2022[18]. - Net profit attributable to shareholders was ¥61,773,364.9, an 85.24% increase from ¥33,347,824.3 in 2023[18]. - The net profit after deducting non-recurring gains and losses was ¥74,680,604.3, showing a significant increase of 159.62% from ¥28,764,969.0 in 2023[18]. - The net cash flow from operating activities was ¥302,163,807, a 206.13% increase compared to -¥284,714,593 in 2023[18]. - The company's revenue for 2024 reached approximately ¥7.82 billion, representing a year-on-year growth of 10.22% compared to ¥7.09 billion in 2023[58]. - Net profit attributable to shareholders increased by 85.24% year-on-year, driven by improved product structure and quality enhancements[51]. - The gross margin for electronic chemicals improved, with the annual sales volume of acetonitrile series products increasing by over 50% due to successful expansion projects[51]. - Sales revenue from specialized chemicals grew by 71.34% year-on-year, contributing significantly to overall revenue growth[59]. Investment and R&D - The company has invested in R&D for new products, with a budget allocation of 10 million RMB for the upcoming year[12]. - Research and development expenses increased by 14.84% to ¥109,902,730.43, indicating a focus on innovation and product development[70]. - The company is focusing on developing new products, including a new etching solution for dual-layer copper metal wiring, which has been completed and aims to enhance market share in electronic chemicals[71]. - A new environmentally friendly high-purity potassium persulfate production process has been developed, targeting the nitrogen removal market, with the project also completed[72]. - The company is developing a micro-reactor for the continuous production of uniform nano-silver, addressing issues of poor dispersion and irregular particle size in existing technologies[77]. - The company is committed to reducing environmental pollution through improved nitrogen oxide purification technologies[75]. Market Expansion and Strategy - The company is focusing on expanding its market presence, particularly in the electronic chemicals sector, which is expected to grow by 20% annually[12]. - The company has established a new subsidiary in Yunnan to enhance its production capabilities and market reach[12]. - The company has a well-established market network, achieving coverage in major domestic cities and expanding into Southeast Asia[49]. - The company aims to enhance its product offerings and service integration to gain a competitive edge, focusing on high brand recognition and comprehensive support services[105]. - The company plans to increase the proportion of high value-added products and improve automation and digitalization to enhance production efficiency and quality control[107]. Risk Management - The company has identified key risks in its operations, including supply chain disruptions, and has outlined mitigation strategies[5]. - The company continues to engage in hedging activities to mitigate price volatility risks associated with raw materials, ensuring stable operations[94]. - The company has established a comprehensive risk management framework for its hedging operations, including market, systemic, technical, operational, and credit risks[95]. - The company faces macroeconomic risks, including potential profit declines and inventory buildup if domestic economic growth slows[108]. - Safety production risks are a concern due to the hazardous nature of chemical products, and the company is enhancing safety measures and training to mitigate these risks[109]. - Environmental risks are heightened due to stricter regulations, prompting the company to adjust its product structure and optimize production processes for energy conservation and emission reduction[111]. Corporate Governance - The company has conducted multiple shareholder meetings to ensure compliance with legal regulations and enhance shareholder engagement[119]. - The sixth board of directors consists of nine members, including three independent directors, and held a total of 8 meetings during the reporting period[120]. - The company emphasizes accurate and timely information disclosure, with the chairman bearing primary responsibility for disclosure matters[125]. - The company maintains independence in its main business operations, including chemical reagent R&D, production, and sales, without reliance on controlling shareholders[127]. - The company has established a complete and independent personnel management system, ensuring that key management personnel do not hold positions in controlling shareholder entities[128]. Environmental Compliance - The company has implemented strict adherence to environmental protection laws, achieving 100% compliance in pollutant discharge[178]. - The wastewater treatment facility of Xilong Science has a designed capacity of 192 tons/day, achieving an effluent concentration of 21.75 mg/L for COD[181]. - The company has invested in environmental protection facilities, with Xilong Science investing 255 units, Foshan Xilong investing 86 units, and Sichuan Xilong investing 43 units for maintenance and updates[185]. - The company has successfully completed its annual emission reduction tasks as per regulations[185]. - The company was recognized as a "Good Environmental Enterprise" by the Sichuan Provincial Ecological Environment Department for the year 2023[188]. Employee Management - The total number of employees at the end of the reporting period is 1,173, with 487 in the parent company and 686 in major subsidiaries[162]. - The professional composition includes 466 production personnel, 266 sales personnel, 145 technical personnel, 58 financial personnel, and 238 administrative personnel[162]. - The company implements annual performance evaluations to determine salary adjustments and bonuses, promoting a performance-driven culture[163]. - The company has established special incentive plans aimed at motivating sales personnel and enhancing their potential[163]. - The training programs implemented during the reporting period aimed to enhance employee skills across various departments, including safety, management, and marketing[164]. Financial Management - The company has fully paid the remuneration for directors, supervisors, and senior management during the reporting period[149]. - The total pre-tax compensation for board members amounted to 5.6794 million yuan[150]. - The company plans to distribute a cash dividend of 0.2 RMB per 10 shares, totaling 11,704,328.44 RMB, based on a total share capital of 585,216,422 shares as of December 31, 2023[165]. - The cash dividend policies are in compliance with the company's articles of association and shareholder resolutions, ensuring clarity and transparency in the decision-making process[167]. - The company has established a comprehensive internal control system that adheres to relevant laws and regulations, with no significant deficiencies reported during the period[170].

西陇科学（002584）公告，2024年营业收入78.16亿元，同比增长10.22%。归属于上市公司股东的净利 润6177.34万元，同比增长85.24%。基本每股收益0.11元/股，同比增长83.33%。公司计划不派发现金红 利，不送红股，不以公积金转增股本。 ...

龙虎榜数据显示，该股因日换手率达20%、日涨幅偏离值达7%上榜龙虎榜2次，买卖居前营业部中，机 构净买入391.72万元，营业部席位合计净买入1192.89万元。 2024年10月30日公司发布的三季报数据显示，前三季度公司共实现营业总收入65.53亿元，同比增长 13.16%，实现净利润0.64亿元，同比增长117.61%。1月18日公司公布了2024年业绩预告，预计实现净利 润0.65亿元至0.95亿元，同比变动区间为94.92%~184.88%。（数据宝） 近日该股表现 西陇科学再度涨停，6个交易日内录得3个涨停，累计涨幅为31.14%，累计换手率为178.60%。截至 11:02，该股今日成交量1.11亿股，成交金额11.24亿元，换手率25.63%。最新A股总市值达63.09亿元，A 股流通市值46.62亿元。 | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.04.23 | -3.73 | 38.98 | -16862.60 | | 2025.04.22 | 10.05 | 28.39 | 15217 ...

西陇科学股份有限公司 关于实际控制人所持股份部分解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：002584 证券简称：西陇科学 公告编号：2025-008 西陇科学股份有限公司（以下简称"公司"或"西陇科学"）现收到控股股 东、实际控制人之一黄少群先生通知，获悉其所持有本公司的部分股份解除质押, 具体事项如下： | 是 否 为 控 股 | 本 次 解 除 | 股东名 | 占其所持 | 占公司总 | 质押起始 | 质 押 | 解 除 | 股 东 及 其 一 | 质 押 | 股 份 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 称 | 股份比例 | 股本比例 | 日 | 日期 | 致行动人 | 数量(股) | | | | | | | 浙江理想 | 10,250,00 | 2023-09- | 黄少群 | 是 | 18.14% | 1.75% | 2025-4-21 | 小额贷款 | | | | | 0 | 20 | ...

证券代码：002584 证券简称：西陇科学 公告编号：2025-007 西陇科学股份有限公司 关于收到民事判决书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、案件所处的诉讼阶段：一审已判决，尚未生效。 2、上市公司所处的当事人地位：被告。 3、涉案金额：12,733,004.91 元。 4、对上市公司损益产生的影响：一审判令被告西陇科学股份有限公司向原 告陈超*、陆健*等 82 名原告赔偿损失共计 7,570,117.10 元，负担案件受理费共 计 137,347.99 元；上述判决系法院作出的一审判决，尚未生效，对公司利润的最 终实际影响需以二审法院最终生效判决结果为准。基于会计处理的谨慎性原则， 公司将根据一审判决情况计提预计负债，预计将对公司 2024 年度净利润产生一 定影响，最终影响金额以会计师事务所年度审计结果为准。 一、本次诉讼的基本情况 西陇科学股份有限公司（以下简称"公司"或"西陇科学"）近日收到广东省汕 头市中级人民法院送达的民事判决书（2023）粤 05 民初 318 号，原告陈超*、陆 健*等 82 名投资者以 ...

1．本次股份质押基本情况 2．股东股份累计质押情况 截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： 股 东 名 称 持股数量 持 股 比例 本次质押前 质押股份数 量（股） 本次质押 后质押股 份数量 占 其 所 持 股 份 比例 占 公 司 总 股 本 比例 已质押股份 情况 未质押股份 情况 已质押 股份限 售数量 占已质 押股份 比例 未质押 股份限 售数量 占 未 质 押 股 份 比例 黄 伟 鹏 38,729,941 6.62% 0 11,100,0 00 28.66 % 1.9% 11,100 ,000 100.00 % 17,947 ,456 64.9 6% 证券代码：002584 证券简称：西陇科学 公告编号：2025-006 西陇科学股份有限公司 实际控制人部分股份质押公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、股东股份质押基本情况 西陇科学股份有限公司（以下简称"公司"）收到实际控制人之一黄伟鹏先 生通知，获悉其所持有本公司的部分股份被质押，具体事项如下： | | | | | | | | 是 | | | | | ...

证券代码：002584 证券简称：西陇科学 公告编号：2025-005 西陇科学股份有限公司 关于合并报表范围内提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 一、 担保情况概述 2024 年 4 月 25 日，西陇科学股份有限公司（以下称"西陇科学"或"公司"） 第六届董事会第二次会议审议通过了《关于公司及子公司对 2024 年度融资授信 提供担保的议案》。2024 年度，根据公司及子（孙）公司的生产经营和资金需求 情况，公司及子（孙）公司为合并报表范围内公司向金融机构申请融资授信提供 担保，担保额度总计不超过人民币 35 亿元。公告内容详见公司 2024 年 4 月 27 日 于指定信息披露媒体披露的《关于公司及子公司对 2024 年度融资授信提供担保 的公告》（公告编号：2024-030），本议案由公司 2023 年度股东大会表决通过。 2024 年 10 月 11 日，公司第六届董事会第五次会议审议通过了《关于增加对 子公司担保额度的公告》，本次增加担保额度后，2024 年度公司及子（孙）公司 为合并报表范围内公司向金融机构申请融资 ...

一、 担保情况概述 2024 年 4 月 25 日，西陇科学股份有限公司（以下称"西陇科学"或"公司"） 第六届董事会第二次会议审议通过了《关于公司及子公司对 2024 年度融资授信 提供担保的议案》。2024 年度，根据公司及子（孙）公司的生产经营和资金需求 情况，公司及子（孙）公司为合并报表范围内公司向金融机构申请融资授信提供 担保，担保额度总计不超过人民币 35 亿元。公告内容详见公司 2024 年 4 月 27 日 于指定信息披露媒体披露的《关于公司及子公司对 2024 年度融资授信提供担保 的公告》（公告编号：2024-030），本议案由公司 2023 年度股东大会表决通过。 2024 年 10 月 11 日，公司第六届董事会第五次会议审议通过了《关于增加对 子公司担保额度的公告》，本次增加担保额度后，2024 年度公司及子（孙）公司 为合并报表范围内公司向金融机构申请融资授信提供担保，担保额度总计不超过 人民币 37.5 亿元。公告内容详见公司 2024 年 10 月 12 日于指定信息披露媒体披 露的《西陇科学：关于增加对子公司担保额度的公告》（公告编号：2024-056）， 本议案由公司 20 ...